SG11201912146RA - Treatment For Migraine - Google Patents

Treatment For Migraine

Info

Publication number
SG11201912146RA
SG11201912146RA SG11201912146RA SG11201912146RA SG11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA SG 11201912146R A SG11201912146R A SG 11201912146RA
Authority
SG
Singapore
Prior art keywords
migraine
treatment
Prior art date
Application number
SG11201912146RA
Inventor
Michael Strupp
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of SG11201912146RA publication Critical patent/SG11201912146RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201912146RA 2017-06-14 2018-06-25 Treatment For Migraine SG11201912146RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1709459.0A GB201709459D0 (en) 2017-06-14 2017-06-14 Treatment for migraine
PCT/IB2018/054676 WO2018229738A1 (en) 2017-06-14 2018-06-25 Treatment for migraine

Publications (1)

Publication Number Publication Date
SG11201912146RA true SG11201912146RA (en) 2020-01-30

Family

ID=59358204

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912146RA SG11201912146RA (en) 2017-06-14 2018-06-25 Treatment For Migraine

Country Status (25)

Country Link
US (1) US11471434B2 (en)
EP (1) EP3638370B1 (en)
JP (1) JP7130739B2 (en)
KR (1) KR102594130B1 (en)
CN (1) CN111093772B (en)
AU (1) AU2018284330B2 (en)
BR (1) BR112019026660A2 (en)
CA (1) CA3067321A1 (en)
CY (1) CY1123860T1 (en)
DK (1) DK3638370T3 (en)
ES (1) ES2847169T3 (en)
GB (1) GB201709459D0 (en)
HR (1) HRP20210108T1 (en)
HU (1) HUE053089T2 (en)
IL (1) IL271211B2 (en)
LT (1) LT3638370T (en)
MA (1) MA49396B1 (en)
MD (1) MD3638370T2 (en)
MX (1) MX2019014784A (en)
PL (1) PL3638370T3 (en)
PT (1) PT3638370T (en)
RS (1) RS61481B1 (en)
SG (1) SG11201912146RA (en)
SI (1) SI3638370T1 (en)
WO (1) WO2018229738A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007721YA (en) * 2018-02-15 2020-09-29 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
WO2020115715A1 (en) * 2018-12-06 2020-06-11 Intrabio Ltd. Deuterated analogs of acetyl-leucine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8701662L (en) * 1987-04-22 1988-10-23 Gelder Nico M Van SETTING AND AGENTS FOR TREATING NEUROLOGICAL DISEASES, EXAMPLE, MIGRAEN THROUGH THE OPERATION OF NERV CELLS
US20040127501A1 (en) * 2002-09-24 2004-07-01 Zhengming Chen Therapeutic agents useful for treating pain
US20060063827A1 (en) 2004-09-23 2006-03-23 Yu Ruey J Systemic administration of therapeutic amino acids and N-acetylamino acids
MY142655A (en) * 2003-06-12 2010-12-15 Euro Celtique Sa Therapeutic agents useful for treating pain
ATE423111T1 (en) * 2003-07-03 2009-03-15 Euro Celtique Sa 2-PYRIDINE ALKYNE DERIVATIVES AND THEIR USE FOR PAIN TREATMENT
EP2080757A1 (en) * 2003-07-24 2009-07-22 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
PT1664016E (en) * 2003-09-22 2008-12-29 Euro Celtique Sa Therapeutic agents useful for treating pain
WO2005030766A1 (en) * 2003-09-22 2005-04-07 Euro-Celtique S.A. Phenyl - carboxamide compounds useful for treating pain
RS50958B (en) * 2003-12-30 2010-10-31 Euro-Celtique S.A. Piperazines useful for treating pain
FR2905600B1 (en) * 2006-09-13 2010-01-15 Pf Medicament TREATMENT OF VERTIGS BY ACETYL-L-LEUCINE.
TN2010000251A1 (en) 2010-06-03 2011-11-11 Rekik Raouf N-ACETYL-DL-LEUCINE MEDICINAL NEURO AND RETINO PROTECTOR
EP2585446A4 (en) * 2010-06-22 2013-12-25 Shionogi & Co Compounds having trpv1 antagonistic activity and uses thereof
EP3875107A1 (en) 2010-06-25 2021-09-08 Shire Human Genetic Therapies, Inc. Pharmaceutical formulation comprising a replacement enzyme for a lysosomal enzyme for use in treating lysosomal storage disease intrathecally
ES2732818T3 (en) 2010-11-09 2019-11-26 Mannkind Corp Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
AU2012293417A1 (en) * 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
CA3021155A1 (en) 2016-04-19 2017-10-26 Intrabio Ltd Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function
RU2021115932A (en) 2016-08-11 2021-06-08 Интрабио Лимитед PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS AGAINST LYSOSOMAL DISEASES OF ACCUMULATION
MA43828B1 (en) 2016-08-11 2019-09-30 Intrabio Ltd Therapeutic agents for neurodegenerative diseases
RS64304B1 (en) 2017-03-28 2023-07-31 Intrabio Ltd Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
RU2763425C2 (en) 2017-10-18 2021-12-29 Интрабио Лимитед Therapeutic agents for neurodegenerative diseases
US20200338034A1 (en) 2017-10-18 2020-10-29 Intrabio Ltd Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders
SG11202007721YA (en) 2018-02-15 2020-09-29 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
WO2020115715A1 (en) 2018-12-06 2020-06-11 Intrabio Ltd. Deuterated analogs of acetyl-leucine
SG11202109512SA (en) 2019-03-02 2021-09-29 Intrabio Ltd Leucine, acetyl leucine, and related analogs for treating disease
WO2020261230A1 (en) 2019-06-28 2020-12-30 Intrabio Ltd. Combination therapy with acetyl-leucine and miglustat
CA3164545A1 (en) 2020-01-13 2021-07-22 Michael Strupp Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Also Published As

Publication number Publication date
CN111093772A (en) 2020-05-01
JP7130739B2 (en) 2022-09-05
JP2020526575A (en) 2020-08-31
KR20210013518A (en) 2021-02-04
WO2018229738A1 (en) 2018-12-20
CN111093772B (en) 2023-11-03
RU2020100475A (en) 2021-07-14
RS61481B1 (en) 2021-03-31
IL271211B2 (en) 2024-01-01
HRP20210108T1 (en) 2021-03-19
US20200253905A1 (en) 2020-08-13
GB201709459D0 (en) 2017-07-26
ES2847169T3 (en) 2021-08-02
EP3638370B1 (en) 2020-11-11
US11471434B2 (en) 2022-10-18
KR102594130B1 (en) 2023-10-24
LT3638370T (en) 2021-03-25
BR112019026660A2 (en) 2020-07-14
IL271211B1 (en) 2023-09-01
CY1123860T1 (en) 2022-05-27
DK3638370T3 (en) 2021-01-25
PT3638370T (en) 2021-01-26
RU2020100475A3 (en) 2021-10-22
EP3638370A1 (en) 2020-04-22
AU2018284330B2 (en) 2024-03-14
MD3638370T2 (en) 2021-04-30
HUE053089T2 (en) 2021-06-28
PL3638370T3 (en) 2021-05-17
MX2019014784A (en) 2021-11-16
SI3638370T1 (en) 2021-04-30
MA49396A (en) 2020-04-22
IL271211A (en) 2020-01-30
AU2018284330A1 (en) 2020-01-02
CA3067321A1 (en) 2018-12-20
MA49396B1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
IL265343A (en) Treating refractory migraine
IL291153A (en) Methods for treating or preventing migraine headache
IL269371A (en) Treatment methods
GB201608885D0 (en) Treatment
GB2567616B (en) Treatment method
GB201811679D0 (en) Treatment apparatus
EP3507838C0 (en) Device for treating parts
GB2571601B (en) Treatment method
SG11202001806TA (en) Treatment method
IL271211A (en) Treatment for migraine
IL270867A (en) Treatment method
PT3250218T (en) Methods for treating obesity
SG10201913372QA (en) Treatment apparatus
GB201718985D0 (en) Treatment
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment
GB201711677D0 (en) Combination treatment
GB201704949D0 (en) Combination treatment
GB201617107D0 (en) Treatment
GB201612260D0 (en) Treatment
GB201612193D0 (en) Treatment
GB201609683D0 (en) Treatment
GB201617380D0 (en) Treatment for Osteoarthritis